NIH – National Cancer Institute: Co-infection & Cancer (R21 clinical trial not allowed)

This opportunity uses the R21 Exploratory/Developmental Research Grants funding mechanism.

The purpose of this Funding Opportunity Announcement (FOA) is to enhance mechanistic and epidemiologic investigations addressing the roles of co-infection. Co-infection is defined as the occurrence of infections by two or more infectious (pathogenic or non-pathogenic) agents – either concurrently or sequentially – and includes both acute and chronic infections by viruses, bacteria, parasites, and/or other microorganisms. Preference will be given to investigations of co-infections with known oncogenic agents (excluding human immunodeficiency virus [HIV]) and of co-infections that engender novel opportunities for prevention and treatment.

Funding & Duration

The combined budget for direct costs for the two-year project period may not exceed US $275,000 (approx. AUD $405,000). No more than US $200,000 (approx. AUD $295,000) may be requested in any single year.


Non-domestic (non-U.S.) Entities (Foreign Institutions) are eligible to apply.

Submission Requirements & Due Date

Further Information

Need Help?

This entry was posted in Funding by Award Type, Funding by Faculty, Grants (Project Funds), Health & Medical Sciences, International Funding and tagged . Bookmark the permalink.

Comments are closed.